- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
The Drug Disease Model Resources (DDMoRe) Repository has been developed to enable access to curated and shared knowledge for the benefit of model-informed drug discovery, development and usage.
The Model Repository is an open, publicly-available, free-to-use platform that is indexed, fully searchable and supported by peer-review. Together with DDMoRe's unique interoperability framework, these tools facilitate the collaborative development of computational models.
Users can submit their models in a number of formats, but to benefit from all of the repository's features will need to use the PharmML representation.
However, please note that currently only PharmML versions up to and including 0.6.1 are correctly recognised and supported. Then, for example, models encoded by PharmML 0.8.1 produced with the DDMoRe Interoperability Framework 5.2 will be labeled in the Repository as "original code" format and the tabs showing the model definition, estimation steps or simulation steps will be not displayed.
DDMoRe relies on the scientific community to build knowledge and fill the repository with relevant content. Thus we welcome models with relevance to the discovery, development and usage of drugs and spanning PK, PD and disease models as well as the range from empirical to systems pharmacology/biology models.
The model submission process is detailed here
Upcoming features include
All models are uploaded/downloaded under the terms of the Creative Commons CC0 Public Domain Dedication
The person who uploaded a model entry, has dedicated the work to the public domain by waiving all of his or her rights to the work worldwide under copyright law. Unless expressly stated otherwise, this person makes no warranties about the work, and disclaims liability for all uses of the work, to the fullest extent permitted by applicable law
The person who downloaded a model entry, can copy, modify, distribute and perform the work, even for commercial purposes, all without asking permission and at his/her own risk
When using or citing a model entry (which we encourage), you should not imply endorsement by the submitter
If you identify some illicit material posted, please email us